Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.

Item
http://www.wikidata.org/entity/Q37354440
Neuraminidase-1: a novel therapeutic target in multistage tumorigenesisExtracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgeryBioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkersEpidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection.Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells.Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancerTranscriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma.The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells.Dependence of Relative Expression of NTR1 and EGFR on Cell Density and Extracellular pH in Human Pancreatic Cancer Cell Lines.EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation.Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling.Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis
P2860

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.

Item
http://www.wikidata.org/entity/Q37354440
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
@en
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
@nl
type
label
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
@en
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
@nl
prefLabel
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
@en
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
@nl
P1433
P1476
P2093
P2860
P304
P31
P478
P577
P698
P932
P1433
P1476
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.
@en
P2093
P2860
P304
P31
P478
P577
P698
P932